Current vaccine pipeline as of December 2018
| RSV vaccine snapshot December 2018 | |||||
| Preclinical | Phase I | Phase II | Phase III | Market approved | |
| Live attenuated | 4 | 6 | 0 | 0 | 0 |
| Inactivated | 1 | 0 | 0 | 0 | 0 |
| Particle | 8 | 1 | 1 | 1 | 0 |
| Subunit | 4 | 5 | 1 | 0 | 0 |
| RNA/DNA | 2 | 0 | 0 | 0 | 0 |
| Live vector | 1 | 1 | 3 | 0 | 0 |
| Combo/Ab prophylax. | 4 | 1 | 3 | 0 | 1 |
| Total, n= 48 | 24 | 14 | 8 | 1 | 1 |
There are 48 vaccine candidates in development involving several different types of vaccine structure as detailed in the left-hand column. As of 2018, only the prophylactic use of palivizumab is market approved. Adapted from108.